01 The ophthalmic drug CDMO market is highly exposed to supply chain disruptions due to its dependence on sterile raw materials, active pharmaceutical ingredients, specialized packaging components, and stringent cold-chain logistics. Disruptions in global sourcing, transportation delays, and shortages of pharmaceutical-grade materials have increased manufacturing lead times and production costs, affecting the timely delivery of ophthalmic products. The market is experiencing a capacity-constrained recovery, driven by expanding production capacity, localized sourcing strategies, and continued investments in resilient supply chain infrastructure to meet growing global demand.
01 Expansion of Sterile Fill-Finish Capabilities for Complex Ophthalmic Therapies The growing pipeline of biologics, sustained-release implants, and gene therapies is driving CDMOs to expand specialized sterile fill-finish manufacturing for ophthalmic products. This transition is enabling pharmaceutical companies to outsource complex production while ensuring regulatory compliance and product quality. As a result, manufacturers are increasing investments in aseptic processing, high-containment facilities, and advanced quality systems to support next-generation eye treatments.
02 Increasing Adoption of Digital Manufacturing and Continuous Quality Monitoring Ophthalmic drug manufacturers are increasingly adopting digital manufacturing platforms that enable real-time process monitoring, electronic batch records, and predictive quality management to improve manufacturing efficiency and regulatory compliance. This transition is helping CDMOs reduce manual documentation, minimize batch deviations, and accelerate product release while ensuring consistent quality for sterile ophthalmic formulations. The growing emphasis on data integrity and automated manufacturing is encouraging wider deployment of Manufacturing Execution Systems and electronic batch records across pharmaceutical production facilities.
01 Expanding Pipeline of Biologics & Advanced Ocular Therapies and Rising Prevalence of Age-related Eye Diseases Drives Market The increasing development of biologics, gene therapies, and sustained-release ophthalmic treatments is driving demand for specialized CDMO services with advanced sterile manufacturing capabilities. These complex therapies require sophisticated process development, aseptic fill-finish, and regulatory expertise beyond the capabilities of many drug developers. As a result, CDMOs are expanding their technical infrastructure and manufacturing capacity to support next-generation ophthalmic products.The increasing incidence of cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy is driving demand for ophthalmic drugs, creating sustained outsourcing opportunities for CDMOs. An aging population and rising diabetes prevalence are expanding the global patient pool requiring long-term ocular therapies. This is encouraging pharmaceutical companies to accelerate product development and scale manufacturing through specialized CDMO partners.
01 High Capital Investment and Complex Technology Transfer for Ophthalmic Formulations Restrain Market Expansion Manufacturing ophthalmic drugs requires significant investment in aseptic production lines, isolator technology, cleanrooms, blow-fill-seal systems, and advanced analytical laboratories. These high infrastructure and maintenance costs create substantial barriers for new entrants and smaller contract manufacturers. Consequently, market expansion remains concentrated among established CDMOs with financial resources to develop and maintain specialized ophthalmic manufacturing facilities.Transferring ophthalmic formulations from laboratory development to commercial manufacturing is technically challenging because small changes in formulation, sterilization processes, or container-closure systems can affect product stability and performance. These complexities increase development timelines, validation requirements, and production risks during scale-up.
01 Expansion of Ophthalmic Gene Therapy Manufacturing and Growth of Biosimilar Ophthalmic Drugs Open New Revenue Opportunities The growing pipeline of gene therapies for inherited retinal diseases and other ocular disorders is creating significant opportunities for ophthalmic CDMOs with viral vector development and sterile manufacturing capabilities. Pharmaceutical and biotechnology companies are increasingly seeking specialized partners that can support process development, GMP manufacturing, and commercial-scale production. As more gene therapies advance through late-stage clinical trials and receive regulatory approvals, CDMOs investing in advanced therapy manufacturing are well positioned for long-term growth.The patent expiry of leading ophthalmic biologics is creating opportunities for CDMOs specializing in biologics process development, analytical testing, and sterile fill-finish manufacturing. Biosimilar developers increasingly rely on contract manufacturing partners to reduce development costs and accelerate regulatory approvals. As more ophthalmic biosimilars enter clinical development and commercialization, CDMOs with expertise in biologics manufacturing and aseptic production are expected to benefit from rising outsourcing demand.
July 2026 Catalent expanded its partnership with Nanoscope Therapeutics to provide late-phase development support, commercial packaging, and distribution for the investigational ophthalmic gene therapy MCO-010.
March 2026 Catalent entered a global collaboration with GelMEDIX to support the development and clinical manufacturing of iPSC-derived cell therapies for ocular and retinal diseases using Catalent's GMP cell therapy platform.